SOURCE: Arrayit Corporation

Arrayit Corporation

August 27, 2009 07:00 ET

Arrayit Technology Speeds Allergy Testing

Airborne and Food Allergens Identified Using Arrayit Instruments

SUNNYVALE, CA--(Marketwire - August 27, 2009) - Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, announces the sale of instruments used to identify allergens in affected individuals.

For allergy testing, allergens are printed onto proprietary glass substrates to form microarrays. Serum samples from individuals with allergies are then reacted with the microarrays to allow binding between the allergens and molecules present in the patient's blood stream. High-speed scanners read the microarrays to determine the nature of the allergic response in each individual. This same procedure can be used to decipher other immune and autoimmune conditions.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal third quarter ended September 30, 2008.

Contact Information